UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 26, 2017
EPIZYME, INC.
(Exact Name of Registrant as Specified in Charter)
| | | | |
| Delaware | | 001-35945 | | 26-1349956 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | |
| 400 Technology Square, Cambridge, Massachusetts | | 02139 |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code:(617) 229-5872
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Epizyme, Inc. (the “Company”) previously disclosed in its annual report on Form10-K for the fiscal year ended December 31, 2016 that Robert Copeland, President of Research and Chief Scientific Officer, would be retiring from the Company on a date to be determined in the second quarter of 2017 to pursue advisory and other opportunities within the industry. The Company and Dr. Copeland have determined that Dr. Copeland’s retirement will be effective June 30, 2017, and that Dr. Copeland will not provide ongoing advisory services to the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | EPIZYME, INC. |
| | | |
| Date: June 28, 2017 | | | | By: | | /s/ Andrew E. Singer |
| | | | | | Andrew E. Singer |
| | | | | | Executive Vice President, Finance and Accounting, Chief Financial Officer and Treasurer |
